Latest Cost Reduction News

MOVE Logistics Group Limited reported a solid FY25 performance with a 61% improvement in normalised earnings despite a challenging economy, setting the stage for a return to profitability in FY26.

Atlas Pearls Ltd reported a 6% revenue increase to $44.3 million in FY25 despite a 30% drop in net profit, unveiling a strategic roadmap targeting up to 50% production growth by FY30 alongside a fully franked dividend.

NTAW Holdings delivered a marked financial turnaround in the second half of FY2025, driven by operational restructuring and cost discipline. The company now sets its sights on consolidating growth and strengthening supplier partnerships in FY2026.

NTAW Holdings Limited has delivered a strong second-half turnaround in FY2025, posting a $30.3 million Operating EBITDA despite a full-year net loss. Under new leadership, the company is setting the stage for consolidation and growth in FY2026.

NTAW Holdings reported a slight revenue increase to $538 million for FY2025 but posted a significant net loss of $44 million, driven by a $39 million impairment charge and operational challenges including the loss of Dunlop distribution rights. The company is executing a business reset focusing on inventory, costs, and cash flow.

Identitii Limited reported a modest 4% revenue increase to $777,542 for FY25, yet its net loss expanded by 8% to $3.82 million, driven by lower investment gains. The company strengthened its cash position through successful capital raising and ongoing cost reductions.

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

The Agency Group Australia Ltd reported a 12% revenue increase and a return to positive EBITDA in FY2025, driven by record property sales and operational efficiencies, despite a net loss after tax of $5.44 million.

Camplify Holdings reported a strategic refocus in FY25, delivering a strong operational turnaround in the second half and positioning itself for profitability in FY26. Despite a decline in gross transaction value, the company improved cost efficiency and expanded its membership and insurance offerings.

Camplify Holdings Limited reported a 12.3% revenue decline to $42.1 million and a near doubling of net loss to $15.8 million in FY25, reflecting a year of strategic transformation including the launch of its MyWay protection product and completion of European platform integration.